Nexus BioPharma, Inc., (OTC-BB: NEXS), a company specializing in the development of a weight loss drug therapy, announced today the appointment of Daniel Einhorn, M.D. to the Company's Scientific & Clinical Advisory Board. Dr. Einhorn is medical director of the Scripps Whittier Diabetes Institute, Clinical Professor of Medicine (voluntary) at UC San Diego, President of Diabetes and Endocrine Associates, and Associate Editor of the Journal of Diabetes.

Dr. Einhorn's experience includes acting as a trustee and past-president of the American College of Endocrinology (ACE), a founding member and current regent of the ACE Foundation, and past-president of the American Association of Clinical Endocrinologists (AACE). He received his BA at Yale (Summa cum Laude), his MD at Tufts (AOA) and his post-graduate training at Harvard. He has been in leadership at AACE and ACE for over 20 years during which time he has participated in writing many national guidelines, including those for diabetes, pre-diabetes, inpatient diabetes management, and obesity. Dr. Einhorn has been on the teaching faculty of every AACE/ACE annual meeting since 1994, chairing the meeting in 2009, and he continues to be a practicing physician.

"We are thrilled that Dan is joining our team of advisors," said Mr. Warren C. Lau, Chief Executive Officer and President of Nexus BioPharma, Inc. "His background and experience will be invaluable as we move our weight loss product candidate into later stage clinical development for treating obesity and type 2 diabetes."

"We need better tools to manage obesity and metabolic diseases, like diabetes," said Dr. Einhorn. "Innovative ideas often come from unexpected pathways."

Nexus BioPharma, Inc. is developing a proprietary drug that activates a key metabolic pathway, the same pathway activated by intense physical exercise.

About Nexus BioPharma, Inc. www.nexusbiopharma.com

Nexus BioPharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property from research and development activities for treating obesity and type 2 diabetes.

The main target for the company's research is the adenosine monophosphate-activated protein kinase (AMPK) pathway. When activated, results include increased metabolism, reduced fat mass and improved blood chemistry.